Business Development

In 1996, Orient EuroPharma Co., Ltd. established the Business Development Department mainly to introduce innovative products and expand foreign markets. The Department strives to arrange pipeline through license-in activities, and since 2009, has acquired marketing rights for the following products in Taiwan and Southeast Asia:

  • Signed agreement with Italian Chiesi Pharmaceutical Company for exclusive rights of Foster® in Taiwan, Malaysia, and Philippines. Foster® was approved in Taiwan and covered by National Healthcare Insurance since 2010. In Malaysia, Foster® was approved and launched in 2011. Foster® was just approved by Philippine authority in 2013 and plan to launch in 2014.

  • Co-develop and Obtain exclusive marketing rights of Micelplatin, a pancreatic cancer drug, in Australia, New Zealand, and other Asian countries except Japan and China from NanoCarrier Co., Ltd. The phase III clinical trials of the drug are ongoing.

  • Co-develop and Obtain exclusive marketing rights of Multikine, an innovative immunotherapy drug for head and neck cancer, in Australia, New Zealand, and other Asian countries except Japan and China from Cel-Sci Company. Taiwan is participating in the global phase III clinical trial of the drug.

  • Signed agreement with Medinox for exclusive rights to NOX-100 in Taiwan, China, Korea, Australia, New Zealand, and Southeast Asia. Currently, Taiwan is conducting the phase II clinical trial.

  • Obtained the exclusive rights of ASC-J9 acne cream in Taiwan, Korea, Australia, New Zealand, and Southeast Asia from AndroScience. The phase II clinical trial is completed and promising, the development project plan to move forward.

  • Obtained the exclusive rights of Cimzia® for rheumatoid arthritis, Vimpat® for epilepsy, and Neupro® for primary Parkinson's disease from UCB Belgium for Taiwan and Southeast Asia subsidiaries.

  • Signed agreement Toray, botained the exclusive right of REMITCH antipruritic drug. Expected to be granted by 2016.

  • Signed agreement with Debiopharm to marketing its cancer drug in Taiwan and Southeast Asia subsidiaries. Permits for these drugs are expected to be granted by 2016.
  • Signed agreement wiht HRA pharma, obtained the exclusive rights of Esmya, new mechanism drug to treat uterine fibroids, which has approved by TFDA.
  • Signed agreement with Beijing Tide Pharma for Anti-Dementia Patch technology transfer and product supply.
For more  information, please contact: licensingin@mail.oep.com.tw

Partnership & Licensing
Looking for partnership in:
  • Micelplatin, Anti-pancreatic cancer drug
  • Multikine, the Head and Neck cancer immunotherapy
  • OP-014, for hypersalivation
  • OP-012, for Attention Deficit Hyperactivity Disorder
For more information, please contact: licensingout@mail.oep.com.tw